{"id":21088,"date":"2025-01-09T21:10:41","date_gmt":"2025-01-09T13:10:41","guid":{"rendered":"https:\/\/flcube.com\/?p=21088"},"modified":"2025-01-09T21:10:43","modified_gmt":"2025-01-09T13:10:43","slug":"biocytogen-and-acepodia-partner-to-develop-dual-payload-bispecific-adcs-for-oncology","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21088","title":{"rendered":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology"},"content":{"rendered":"\n

China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315<\/a>) has entered into a partnership with Acepodia, a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).<\/p>\n\n\n\n

Combining Expertise<\/strong>
The partnership combines Biocytogen\u2019s RenLite platform with Acepodia\u2019s Antibody-Dual-Drugs Conjugation (AD2C) technology. This strategic combination is expected to address some of the most challenging issues in oncology, specifically tumor heterogeneity and drug resistance, by employing a dual-payload approach.<\/p>\n\n\n\n

Significance of the Partnership<\/strong>
This collaboration underscores the commitment of both Biocytogen and Acepodia to advancing innovative therapies in oncology. By leveraging their respective technologies, the companies aim to develop more effective treatments that can overcome the complexities of tumor heterogeneity and drug resistance, ultimately improving patient outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"

China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia,…<\/p>\n","protected":false},"author":1,"featured_media":21090,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[3101,1519,1214],"class_list":["post-21088","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-acepodia","tag-biocytogen-pharmaceuticals","tag-hkg-2315"],"yoast_head":"\nBiocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia (6976.TT), a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21088\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia (6976.TT), a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21088\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-09T13:10:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-09T13:10:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"460\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology\",\"datePublished\":\"2025-01-09T13:10:41+00:00\",\"dateModified\":\"2025-01-09T13:10:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088\"},\"wordCount\":151,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0910.png\",\"keywords\":[\"Acepodia\",\"Biocytogen Pharmaceuticals\",\"HKG: 2315\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21088#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21088\",\"name\":\"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0910.png\",\"datePublished\":\"2025-01-09T13:10:41+00:00\",\"dateModified\":\"2025-01-09T13:10:43+00:00\",\"description\":\"China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia (6976.TT), a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21088\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0910.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/0910.png\",\"width\":1080,\"height\":460,\"caption\":\"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21088#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology - Insight, China's Pharmaceutical Industry","description":"China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia (6976.TT), a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21088","og_locale":"en_US","og_type":"article","og_title":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology","og_description":"China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia (6976.TT), a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).","og_url":"https:\/\/flcube.com\/?p=21088","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-09T13:10:41+00:00","article_modified_time":"2025-01-09T13:10:43+00:00","og_image":[{"width":1080,"height":460,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21088#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21088"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology","datePublished":"2025-01-09T13:10:41+00:00","dateModified":"2025-01-09T13:10:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21088"},"wordCount":151,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21088#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png","keywords":["Acepodia","Biocytogen Pharmaceuticals","HKG: 2315"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21088#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21088","url":"https:\/\/flcube.com\/?p=21088","name":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21088#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21088#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png","datePublished":"2025-01-09T13:10:41+00:00","dateModified":"2025-01-09T13:10:43+00:00","description":"China\u2019s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with Acepodia (6976.TT), a cell therapy specialist operating out of Taipei and California, US. The collaboration aims to provide innovative solutions for tumor heterogeneity and drug resistance through the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21088#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21088"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21088#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png","width":1080,"height":460,"caption":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21088#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen and Acepodia Partner to Develop Dual-Payload Bispecific ADCs for Oncology"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/0910.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21088","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21088"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21088\/revisions"}],"predecessor-version":[{"id":21091,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21088\/revisions\/21091"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21090"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21088"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21088"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21088"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}